CONCLUSIONS	In patients with idiopathic pulmonary fibrosis , BIBF 1120 at a dose of 150 mg twice daily , as compared with placebo , was associated with a trend toward a reduction in the decline in lung function , with fewer acute exacerbations and preserved quality of life .\